SARS-COV-2 업데이트

Benjamin Boettner, The Wyss Institute for Biologically Inspired Engineering at Harvard University

"A method to capture CoV2 virus particles from human samples in a single step and identify them within 1 hour is being explored by Senior Staff Scientist Michael Super, Ph.D., working on Ingber’s Bioinspired Therapeutics & Diagnostics platform. The researchers are leveraging the Wyss Institute’s FcMBL pathogen capture technology to bind CoV2 virus particles, which they hope to be able to rapidly identify using mass spectrometry. FcMBL is a genetically engineered variant of the “Mannose Binding Lectin” (MBL) immune protein that binds to molecules on the surface of over 100 different pathogens, including certain viruses. Ingber’s team has confirmed that FcMBL binds to a non-infectious pseudotyped CoV2 virus that displays the CoV2 Spike protein on its surface."

https://wyss.harvard.edu/news/news-the-wyss-institutes-response-to-covid-19-beating-back-the-coronavirus/

Vector Laboratories의 다양한 Mannose Binding Lectin을 확인해 보시기 바랍니다.

Vector Laboratories 제품 및 견적 문의는 코메드로 연락 주시기 바랍니다.

(주)코메드    l    경기도 성남시 중원구 둔촌대로 555 선일테크노피아 805호

E. service@kormed.com   l   T. 031-777-3101   l   F. 031-777-3999   l   http://www.kormed.com